MICHAEL JOHNSON to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications MICHAEL JOHNSON has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
1.104
-
Patterns of Lipid Lowering Therapy Use Among Older Adults in a Managed Care Advantage Plan in the United States. J Pharm Pract. 2024 Feb; 37(1):123-131.
Score: 0.490
-
Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study. Drugs Aging. 2015 Sep; 32(9):743-54.
Score: 0.299
-
Evaluating adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments and intermediate outcomes among elderly patients using marginal structural modeling. Pharmacotherapy. 2022 07; 42(7):518-528.
Score: 0.120
-
Enhancing Statin Adherence Using a Motivational Interviewing Intervention and Past Adherence Trajectories in Patients with Suboptimal Adherence. J Manag Care Spec Pharm. 2019 Oct; 25(10):1053-1062.
Score: 0.099
-
Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol. 2009 May; 104(5):1241-8.
Score: 0.048
-
Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009 May; 136(5):1601-8.
Score: 0.047